Clearside Biomedical, Inc. reported its financial results for the third quarter and the nine months ended September 30, 2025, revealing a net loss of $5.97 million for the quarter, a decrease from a loss of $7.69 million in the same period last year. For the nine-month period, the company recorded a net loss of $18.69 million, compared to a loss of $27.05 million in the prior year. The company’s total revenue for the third quarter was $201,000, a significant decline from $1.04 million in the same quarter of 2024. For the nine months, revenue increased to $3.02 million from $1.36 million, primarily due to milestone payments and other revenue from license agreements.
The company’s operating expenses for the third quarter rose to $7.24 million, up from $6.97 million in the previous year, driven by increased general and administrative costs, which rose to $4.31 million from $2.84 million. Research and development expenses decreased to $2.93 million from $4.13 million, reflecting a reduction in costs associated with clinical trials. The total operating loss for the quarter was $7.04 million, compared to a loss of $5.93 million in the prior year. The company’s accumulated deficit as of September 30, 2025, stood at $373.97 million.
In terms of strategic developments, Clearside Biomedical has paused all internal research and development programs as part of a broader strategy to explore various alternatives to enhance shareholder value. This includes potential asset sales, partnerships, or other strategic transactions. The company has retained Piper Sandler to assist in this evaluation process. Additionally, in July 2025, the company underwent a reduction in force, transitioning all employees to consulting roles, which incurred $2.3 million in severance costs.
Operationally, Clearside Biomedical's cash and cash equivalents decreased to $6.8 million as of September 30, 2025, down from $20.02 million at the end of 2024. The company’s total liabilities increased to $65.59 million from $63.98 million at the end of the previous fiscal year. The company has also entered into an Omnibus Amendment Agreement to facilitate the sale of certain rights related to its SCS Microinjector technology, receiving an additional $2.9 million in the process.
Looking ahead, Clearside Biomedical faces significant challenges, including the need for additional financing to sustain operations. The company has indicated that it does not expect its current cash reserves to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern. The company plans to pursue various financing options, including equity offerings and potential collaborations, to support its ongoing operations and development efforts.
About Clearside Biomedical, Inc.
Clearside Biomedical develops innovative ophthalmic therapies and delivery platforms, primarily utilizing its proprietary suprachoroidal space injection technology. Its core product, XIPERE, treats macular edema associated with uveitis. The company partners globally for development and commercialization, leveraging its SCS Microinjector for targeted, non-surgical drug delivery to the back of the eye, aiming to improve efficacy, safety, and patient access in retinal and choroidal diseases.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.